A Review Of GW7647
All enrolled people who received a minimum of just one dose of zosuquidar or placebo during induction have been monitored for that prevalence of adverse activities (439 individuals, 219 on zosuquidar and 210 on placebo). The most typical adverse gatherings were being associated with the period of prolonged and substantial myelosuppression as is ant